1Jackson GH. Use of fludarabine in the treatment of acute myeloid leukemia. Hematol J ,2004,5 ( Suppl 1 ) :S62-S67.
2Belhabri A,Thomas X,Wattel E, et al. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: aphase Ⅱ randomized trial. Hematol J ,2002,3:49-55.
3Gandhi V, Estey E, Keating M J, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol,1993 ,11:116-124.
4Yamada K, Furusawa S, Saito K, et all. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study. Leukemia, 1995,9 : 10-14.
5Attal M,Harousseau JL,Stoppa AM. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.Intergroupe Francais du Myelome[J].New England Journal of Medicine,1996,(02):91-97.
6Greipp PR,San Miguel J,Dufie BG. International staging system for multiple myeloma[J].Journal of Clinical Oncology,2005,(15):3412-3420.
7张之南.血液病诊断及疗效标准[M]北京:科学出版社,2007233-235.
8Bjorkstrand B,Rasmussen T,Remes K. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma:a randomized phase pilot Ⅱ-study[J].European Journal of Haematology,2003,(06):379-383.
